Publicado el 22 junio 2017

VIVEbiotech´s work presented at European Hematology Association (EHA) Congress

As commented in the prior press release published at our webpage, here it is enclosed the poster `presented at European Haematology Association (EHA) Congress.

The poster entitled “Optimization of Transduction Conditions With GMP Like Lentiviral Vectors For The Gene Therapy Of Piruvate Kinase Deficiecy” was presented at European Hematology Association congress hold in Madrid from 22nd to the 25th of June.

The authors of these posters are:

Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
Unidad Mixta de Terapias Avanzadas. Instituto de Investigación Sanitaria Fundación Jiménez
VIVEbiotech (responsible for the manufacturing of Lentiviral vectors)

As shown in the poster, this work has been financed with the support of the USA-based leader Company in Gene Therapy, Rocket Pharma.